Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin-6 - Yeda

Drug Profile

Interleukin-6 - Yeda

Alternative Names: IL-6; r-hIL6; Recombinant human interleukin-6; Sigosix®; SJ0031; β2-interferon

Latest Information Update: 05 Dec 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yeda
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Haematological disorders; Haematological malignancies; Preleukaemia; Thrombocytopenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Mar 2000 Suspended-I for Cancer in USA (Unknown route)
  • 01 Mar 2000 Suspended-II for Cancer in European Union (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top